What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity [defined as a body mass index (BMI) ≥ 30 kg/m(2)] represents a considerable public health problem and is associated with a significant range of comorbidities and an increased mortality risk. The primary aim of the management of obesity is to achieve weight reduction in the interests of health. For obese patients who cannot achieve or maintain a healthy weight by non-pharmacological means, drug therapy is recommended in combination with non-pharmacological interventions such as dietary modifications and exercise. OBJECTIVE: To evaluate the clinical effectiveness and cost-effectiveness of three pharmacological interventions in obese patients. DATA SOURCES: Clinical effectiveness data used in the meta-analysis were sourced from articles identified in a systematic review of the literature. Data used to inform transitions to obesity-related comorbidities were derived from the General Practice Research Database (GPRD). The results of the meta-analysis and GPRD analyses informed the economic model supplemented by data from the Health Survey for England and other UK-specific data sourced from the literature. REVIEW METHODS: A systematic literature review was conducted of the clinical effectiveness and cost-effectiveness of orlistat, sibutramine and rimonabant within their licensed indications for the treatment of obese patients. Electronic bibliographic databases including MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, The Cochrane Library databases and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched in January 2009, and the reference lists of relevant articles were checked. Studies were included if they compared orlistat, sibutramine or rimonabant with lifestyle and/or exercise advice (standard care), placebo or metformin. RESULTS: Overall, 94 studies involving 24,808 individuals were included in the clinical meta-analysis. Eighty-three trials included data on weight change, 41 included data on BMI change and 45 and 36 studies reported on 5% and 10% body weight loss, respectively. Overall, the results show that the active drug interventions are all effective at reducing weight and BMI compared with placebo. In the case of sibutramine, the higher dose (15 mg) resulted in a greater reduction than the lower dose (10 mg). Generally, the data quality of the trials included was low with poor reporting of standard errors and standard deviations. Results from the BMI risk models derived from the GPRD showed consistent increases in risk with increasing BMI. Adjustments for key confounders, such as age, sex and smoking status, were found to be statistically significant at the 5% level, in all risk models. Applying linear models to estimate BMI trajectories, for the diabetic cohort, an average increase in BMI of 0.040 per year for both men and women was observed. The non-diabetic cohort model showed an increase in BMI of 0.175 per year for women and 0.145 per year for men. The results of the cost-effectiveness analyses suggest that sibutramine 15 mg dominates the other three active interventions and the net benefit analyses show that sibutramine 15 mg is the most cost-effective alternative for thresholds > £2000 per quality-adjusted life-year (QALY). However, both sibutramine and rimonabant have been withdrawn because of safety concerns relating to potential treatment-induced fatal adverse events. If the proportion of patients who experienced a fatal adverse event was > 1.8% (1.5%, 1.0%) for sibutramine 15 mg (sibutramine 10 mg, rimonabant) the treatment would not be considered cost-effective when using a threshold of £20,000 per QALY. LIMITATIONS: The clinical review did not include all possible lifestyle comparators, with the inclusion limited to only those trials included one of the active drug interventions. We also excluded all studies not reported in English. Although the clinical review included data from 94 studies, the quality of data was generally low, particularly in terms of the reporting of standard deviation. There was also inconsistency between the results of the mixed-treatment comparison (MTC) and the pair-wise analyses. CONCLUSION: The MTC of anti-obesity treatments shows that all the active treatments are effective at reducing weight and BMI. The economic results show that, compared with placebo, the treatments are all cost-effective when using a threshold of £20,000 per QALY, and, within the limitations of the data available, sibutramine 15 mg dominates the other three interventions. This work has highlighted many areas of methodological research that could be explored, including assessing inconsistencies within a network to determine differences between the results of pair-wise and MTC analyses; the use of meta-regression methods to look for effect modifiers; exploring the effect of local publication bias; and the use of joint models to analyse the repeated measures of BMI and the time-to-event processes simultaneously. FUNDING: The
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Weinstein, M. C., O'Brien, B., Hornberger, J., Jackson, J., Johannesson, M., McCabe, C., & Luce, B. R. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.00234.x · Cited by 1,172
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Health risks associated with overweight and obesity
Kopelman, P. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00311.x · Cited by 731
Meta-analysis: The Effect of Dietary Counseling for Weight Loss
Dansinger, M. L., Tatsioni, A., Wong, J. B., Chung, M., & Balk, E. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-1-200707030-00007 · Cited by 467
Quality of reporting of observational longitudinal research.
Tooth, L. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi042 · Cited by 363
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
Hanefeld, M., & Sachse, G. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00237.x · Cited by 151
Cited by
Vilmann, P., Frost Clementsen, P., Colella, S., Siemsen, M., De Leyn, P., Dumonceau, J.-M., Herth, F. J., Larghi, A., Vazquez-Sequeiros, E., Hassan, C., et al. (2015) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezv194 · Cited by 293
Brain–gut–microbiome interactions in obesity and food addiction
Gupta, A., Osadchiy, V., & Mayer, E. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0341-5 · Cited by 262
Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity
Seifarth, C., Schehler, B., & Schneider, H. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1327734 · Cited by 258
Booth, H. P., Prevost, T. A., Wright, A. J., & Gulliford, M. C. (2014) · Family Practice · doi:10.1093/fampra/cmu064 · Cited by 144
Booth, H. P., Prevost, A. T., & Gulliford, M. C. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006642 · Cited by 121
“3 Several studies have evaluated the effectiveness of primary care interventions for weight management in obesity, 4 – 8 but few studies have evaluated how overweight and obese patients are managed in primary care.”
BackgroundShared decision making in endocrinology: Present and future directions
Rodriguez-Gutierrez, R., Gionfriddo, M. R., Ospina, N. S., Maraka, S., Tamhane, S., Montori, V. M., & Brito, J. P. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00468-4 · Cited by 117
Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.7.740 · Cited by 81
Jiskoot, G., Benneheij, S. H., Beerthuizen, A., de Niet, J. E., de Klerk, C., Timman, R., Busschbach, J. J., & Laven, J. S. E. (2017) · Reproductive Health · doi:10.1186/s12978-017-0295-4 · Cited by 50
“Insulin resistance might play a mediating role in the effect of obesity on metabolic and reproductive symptoms in PCOS [21].”
BackgroundWilson, E. R., Kyle, T. K., Nadglowski, J. F., & Stanford, F. C. (2017) · Obesity · doi:10.1002/oby.21746 · Cited by 29
“Excluding obesity treatments from health insurance also undermines an objective of the U.S. Department of Health and Human Services and the ACA: reduce the growth of healthcare costs while promoting high-quality, effective care (15,35).”
BackgroundInfluentialCadegiani, F. A., Diniz, G. C., & Alves, G. (2017) · BMC Obesity · doi:10.1186/s40608-017-0147-3 · Cited by 15
Watkins, S., Toliver, J. C., Kim, N., Whitmire, S., & Garvey, W. T. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.22116 · Cited by 10
Metadata
- Authors
- Ara, R., Blake, L., Gray, L., Hernández, M., Crowther, M., Dunkley, A., Warren, F., Jackson, R., Rees, A., Stevenson, M., Abrams, K., Cooper, N., Davies, M., Khunti, K., & Sutton, A.
- Venue
- Health Technology Assessment
- Published
- 2012-02
- Volume
- 16
- Issue
- 5
- Pages
- iii-xiv, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2012312152
- Cited by
- 94
- References
- 9
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.